Humatrope

Humatrope is a prescription injectable solution containing the recombinant human growth hormone somatropin. It is supplied as a sterile solution for subcutaneous injection, marketed in the European Union. The product provides a synthetic form of the naturally occurring growth hormone, enabling replacement therapy for individuals with growth hormone deficiency or related endocrine conditions. Humatrope is classified as a growth hormone (ATC code H01AC01) and is administered under medical supervision.

Humatrope is indicated for several endocrine and growth‑related disorders where endogenous growth hormone production is insufficient or absent. It is used in both pediatric and adult patients to support normal growth and metabolic function. - Treatment of growth hormone deficiency in children to promote linear growth. - Treatment of growth hormone deficiency in adults to improve body composition and quality of life. - Management of growth failure associated with Turner syndrome. - Management of growth failure associated with Prader‑Willi syndrome. - Treatment of short stature due to chronic renal insufficiency. - Treatment of idiopathic short stature when other causes have been excluded.

Adverse reactions to Humatrope are generally dose‑related and may involve injection‑site or systemic symptoms, varying in frequency and severity. Common: - Localized pain, redness, or swelling at the injection site, usually resolving within a few days. - Headache of mild to moderate intensity, often transient. - Transient joint or muscle aches that may occur after dosing. - Mild nausea, abdominal discomfort, or other gastrointestinal symptoms. Serious: - Intracranial hypertension presenting with severe headache, visual changes, or papilledema. - Development of glucose intolerance, new‑onset diabetes mellitus, or worsening of existing diabetes. - Elevated blood pressure or worsening of pre‑existing hypertension, requiring medical review. - Severe hypersensitivity reactions, including rash, urticaria, or anaphylaxis.

When prescribing Humatrope, clinicians should evaluate patient history and monitor for conditions that could be aggravated by growth hormone therapy. - Assess for active malignancy, as growth hormone may accelerate tumor growth. - Screen for intracranial hypertension before initiating therapy and monitor visual symptoms. - Evaluate glucose metabolism; patients with diabetes may require closer glycemic control. - Monitor blood pressure regularly, especially in individuals with pre‑existing hypertension. - Use caution in patients with a history of slipped capital femoral epiphysis or other orthopedic disorders. - Consider the risk of edema in patients with renal or cardiac impairment.

Humatrope may interact with other medications or substances that affect its absorption, metabolism, or the physiological pathways it influences. Avoid: - Concomitant use of glucocorticoids at high doses, which can antagonize growth‑hormone effects. - Co‑administration with insulin‑like growth factor‑1 (IGF‑1) therapy, which may increase risk of hypoglycemia. - Use with oral estrogen therapy in high doses, as it can reduce the efficacy of growth hormone. Use with caution: - Antidiabetic agents, because Humatrope can alter glucose tolerance; monitor blood sugar. - Antihypertensive medications, as blood pressure may rise during therapy. - Medications that cause fluid retention (e.g., thiazide diuretics), requiring observation for edema.